Etanercept

Generic Name: Etanercept

Brand Names: Enbrel, Eticovo, Benepali, Erelzi, Nepexto

Drug Type: Biotech

Chemical Formula: -

CAS Number: 185243-69-0

Unique Ingredient Identifier: OP401G7OJC

Background: Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).

Indication: Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is also used to manage the symptoms of psoriatic arthritis and ankylosing spondylitis.

Associated Conditions: Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis

Associated Therapies: -

Clinical Trials

Circadian RA Study in Rheumatoid Arthritis Subjects

Withdrawn

Conditions: Rheumatoid Arthritis

First Posted Date: 2017-06-07

Last Posted Date: 2019-06-14

Lead Sponsor: University of California, Davis

Registration Number: NCT03178955

Locations: 🇺🇸
UC Davis Center for Musculoskeletal Health, Sacramento, California, United States

Niclosamide With Etanercept in Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis (RA)

Interventions: Drug: Placebo
Drug: Niclosamide
Drug: Etanercept

First Posted Date: 2017-05-19

Last Posted Date: 2018-12-12

Lead Sponsor: Faiq Gorial

Target Recruit Count: 110

Registration Number: NCT03160001

Locations: 🇮🇶
Baghdad teaching Hospital, Baghdad, Iraq

Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation

Phase 4

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Drug: Tocilizumab
Drug: Etanercept
Drug: Infliximab
Drug: Adalimumab
Drug: Golimumab
Drug: Certolizumab Pegol

First Posted Date: 2017-04-04

Last Posted Date: 2022-09-19

Lead Sponsor: Mario Negri Institute for Pharmacological Research

Target Recruit Count: 208

Registration Number: NCT03100253

Locations: 🇮🇹
Policlinico Sant'Orsola Malpighi, Bologna, Italy
🇮🇹
Azienda Consorziale Ospedaliera Policlinico, Bari, Italy
🇮🇹
Azienda Socio Sanitaria Territoriale - Papa Giovanni XXIII, Bergamo, Italy

and more 19 locations

Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Placebo
Drug: Ixekizumab
Drug: Etanercept

First Posted Date: 2017-03-08

Last Posted Date: 2021-09-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 201

Registration Number: NCT03073200

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Modern Research Associates PLLC, Dallas, Texas, United States
🇲🇽
Hospital Univ. Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico

and more 66 locations

NATIENS: Optimal Management and Mechanisms of SJS/TEN

Phase 3

Terminated

Conditions: Stevens-Johnson Syndrome
Toxic Epidermal Necrolyses

Interventions: Drug: Harmonized supportive care
Drug: Etanercept 50 mg sc day 1 and day 4

First Posted Date: 2016-12-08

Last Posted Date: 2025-01-07

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 2

Registration Number: NCT02987257

Locations: 🇺🇸
University of California, Davis Medical Center, Sacramento, California, United States
🇺🇸
Valleywise Health Medical Center, Phoenix, Arizona, United States
🇺🇸
MedStar Washington Hospital Center, Washington, District of Columbia, United States

and more 11 locations

Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Following-up Study

Phase 4

Completed

Conditions: Recurrence
Spondylitis, Ankylosing

Interventions: Drug: Etanercept

First Posted Date: 2016-09-27

Last Posted Date: 2016-11-16

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 35

Registration Number: NCT02915354

Locations: 🇨🇳
Rheumatology Department, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Treatment Tapering in JIA With Inactive Disease

Phase 3

Completed

Conditions: Juvenile Idiopathic Arthritis

Interventions: Drug: etanercept
Drug: adalimumab
Drug: Abatacept
Drug: Tocilizumab

First Posted Date: 2016-07-21

Last Posted Date: 2021-04-01

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 62

Registration Number: NCT02840175

Locations: 🇫🇷
Necker Children's Hospital, Paris, France

Omental Islet Transplant

Phase 1

Completed

Conditions: Type 1 Diabetes

Interventions: Procedure: Omental Islet transplant
Drug: Anti-Thymocyte Globulin
Drug: Mycophenolate mofetil
Drug: Tacrolimus
Drug: Etanercept
Drug: Sirolimus

First Posted Date: 2016-07-01

Last Posted Date: 2022-05-09

Lead Sponsor: University of Alberta

Target Recruit Count: 4

Registration Number: NCT02821026

Locations: 🇨🇦
Clinical Islet Transplant Program, Edmonton, Alberta, Canada

A Pilot Study of MSCs Iufusion and Etanercept to Treat Ankylosing Spondylitis

Phase 2

Conditions: Spondylitis
Spondylitis, Ankylosing
Ankylosis
Arthritis
Spondylarthritis
Spondylarthropathies
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases

Interventions: Biological: Intravenous infusion of MSCs
Drug: Etanercept

First Posted Date: 2016-06-22

Last Posted Date: 2016-06-24

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 250

Registration Number: NCT02809781

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Rhupus Syndrome and Efficacy of Etanercept Treatment

Completed

Conditions: Rhupus Syndrome, Etanercept

Interventions: Drug: etanercept

First Posted Date: 2016-05-09

Last Posted Date: 2016-05-09

Lead Sponsor: Yang Beibei

Target Recruit Count: 6

Registration Number: NCT02766439

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy